CA2669069C - Process for the preparation of 2-imino-thiazolidin-4-one derivatives - Google Patents
Process for the preparation of 2-imino-thiazolidin-4-one derivatives Download PDFInfo
- Publication number
- CA2669069C CA2669069C CA2669069A CA2669069A CA2669069C CA 2669069 C CA2669069 C CA 2669069C CA 2669069 A CA2669069 A CA 2669069A CA 2669069 A CA2669069 A CA 2669069A CA 2669069 C CA2669069 C CA 2669069C
- Authority
- CA
- Canada
- Prior art keywords
- thiazolidin
- hydroxy
- benz
- ylidene
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims abstract description 87
- 238000002360 preparation method Methods 0.000 title claims abstract description 23
- HYMJHROUVPWYNQ-UHFFFAOYSA-N 2-amino-1,3-thiazol-4-one Chemical class NC1=NC(=O)CS1 HYMJHROUVPWYNQ-UHFFFAOYSA-N 0.000 title abstract description 8
- 150000001875 compounds Chemical class 0.000 claims abstract description 94
- 239000000543 intermediate Substances 0.000 claims abstract description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 36
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 34
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 30
- 229910052736 halogen Inorganic materials 0.000 claims description 21
- 150000002367 halogens Chemical class 0.000 claims description 21
- 229910052739 hydrogen Inorganic materials 0.000 claims description 17
- 239000001257 hydrogen Substances 0.000 claims description 17
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 17
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 17
- 238000006243 chemical reaction Methods 0.000 claims description 16
- 239000002904 solvent Substances 0.000 claims description 13
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 12
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 10
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 9
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 9
- LSTRKXWIZZZYAS-UHFFFAOYSA-N 2-bromoacetyl bromide Chemical compound BrCC(Br)=O LSTRKXWIZZZYAS-UHFFFAOYSA-N 0.000 claims description 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 6
- -1 C1-7-alkoxy Inorganic materials 0.000 claims description 5
- 125000001424 substituent group Chemical group 0.000 claims description 5
- TXKYJCYKCWRQQX-UHFFFAOYSA-N 3-phenyl-2-propylimino-1,3-thiazolidin-4-one Chemical compound CCCN=C1SCC(=O)N1C1=CC=CC=C1 TXKYJCYKCWRQQX-UHFFFAOYSA-N 0.000 claims description 3
- SUCNSVQGABWGJV-OWBHPGMISA-N CC(C)\N=C1/SCC(=O)N1C1=CC=CC(Cl)=C1 Chemical compound CC(C)\N=C1/SCC(=O)N1C1=CC=CC(Cl)=C1 SUCNSVQGABWGJV-OWBHPGMISA-N 0.000 claims description 3
- OYBHACSOBWDLDC-YPKPFQOOSA-N CCC\N=C1/SCC(=O)N1C1=CC=CC=C1C Chemical compound CCC\N=C1/SCC(=O)N1C1=CC=CC=C1C OYBHACSOBWDLDC-YPKPFQOOSA-N 0.000 claims description 3
- 238000002955 isolation Methods 0.000 claims description 3
- 238000000746 purification Methods 0.000 claims description 3
- ZBINHKVUAGKHME-SEYXRHQNSA-N CC(C)\N=C1/SCC(=O)N1C1=CC=CC=C1 Chemical compound CC(C)\N=C1/SCC(=O)N1C1=CC=CC=C1 ZBINHKVUAGKHME-SEYXRHQNSA-N 0.000 claims description 2
- AUMLCWGHDDYHMK-YPKPFQOOSA-N CC(C)\N=C1/SCC(=O)N1C1=CC=CC=C1C Chemical compound CC(C)\N=C1/SCC(=O)N1C1=CC=CC=C1C AUMLCWGHDDYHMK-YPKPFQOOSA-N 0.000 claims description 2
- KWHSAFDHCJEIBQ-YPKPFQOOSA-N CCCC\N=C1/SCC(=O)N1C1=CC=CC=C1 Chemical compound CCCC\N=C1/SCC(=O)N1C1=CC=CC=C1 KWHSAFDHCJEIBQ-YPKPFQOOSA-N 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 229920006395 saturated elastomer Polymers 0.000 claims description 2
- 125000006701 (C1-C7) alkyl group Chemical group 0.000 claims 12
- 150000002431 hydrogen Chemical group 0.000 claims 9
- 125000000217 alkyl group Chemical group 0.000 claims 8
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 1
- NOLHRFLIXVQPSZ-UHFFFAOYSA-N 1,3-thiazolidin-4-one Chemical class O=C1CSCN1 NOLHRFLIXVQPSZ-UHFFFAOYSA-N 0.000 abstract description 2
- 229940125721 immunosuppressive agent Drugs 0.000 abstract description 2
- 239000003018 immunosuppressive agent Substances 0.000 abstract description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 25
- 238000005160 1H NMR spectroscopy Methods 0.000 description 21
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 21
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 239000000203 mixture Substances 0.000 description 7
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 6
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 239000001632 sodium acetate Substances 0.000 description 6
- 235000017281 sodium acetate Nutrition 0.000 description 6
- 239000000725 suspension Substances 0.000 description 5
- RGHHSNMVTDWUBI-UHFFFAOYSA-N 4-hydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1 RGHHSNMVTDWUBI-UHFFFAOYSA-N 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 3
- SEPPVOUBHWNCAW-FNORWQNLSA-N (E)-4-oxonon-2-enal Chemical compound CCCCCC(=O)\C=C\C=O SEPPVOUBHWNCAW-FNORWQNLSA-N 0.000 description 2
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 2
- LLBZPESJRQGYMB-UHFFFAOYSA-N 4-one Natural products O1C(C(=O)CC)CC(C)C11C2(C)CCC(C3(C)C(C(C)(CO)C(OC4C(C(O)C(O)C(COC5C(C(O)C(O)CO5)OC5C(C(OC6C(C(O)C(O)C(CO)O6)O)C(O)C(CO)O5)OC5C(C(O)C(O)C(C)O5)O)O4)O)CC3)CC3)=C3C2(C)CC1 LLBZPESJRQGYMB-UHFFFAOYSA-N 0.000 description 2
- 238000012369 In process control Methods 0.000 description 2
- 238000006000 Knoevenagel condensation reaction Methods 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 150000003973 alkyl amines Chemical class 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- 238000010965 in-process control Methods 0.000 description 2
- 150000002540 isothiocyanates Chemical class 0.000 description 2
- 239000012454 non-polar solvent Substances 0.000 description 2
- 238000005580 one pot reaction Methods 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
- 0 CN(C(C(S1)=Cc(cc2*)ccc2O)=*)C1=N* Chemical compound CN(C(C(S1)=Cc(cc2*)ccc2O)=*)C1=N* 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 229910052792 caesium Inorganic materials 0.000 description 1
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- HPYNZHMRTTWQTB-UHFFFAOYSA-N dimethylpyridine Natural products CC1=CC=CN=C1C HPYNZHMRTTWQTB-UHFFFAOYSA-N 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/54—Nitrogen and either oxygen or sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IB2006054409 | 2006-11-23 | ||
| IBPCT/IB2006/054409 | 2006-11-23 | ||
| PCT/IB2007/054752 WO2008062376A2 (en) | 2006-11-23 | 2007-11-22 | New process for the preparation of 2-imino-thiazolidin-4-one derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2669069A1 CA2669069A1 (en) | 2008-05-29 |
| CA2669069C true CA2669069C (en) | 2015-02-17 |
Family
ID=39316391
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2669069A Active CA2669069C (en) | 2006-11-23 | 2007-11-22 | Process for the preparation of 2-imino-thiazolidin-4-one derivatives |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US8263780B2 (Direct) |
| EP (2) | EP2094676B1 (Direct) |
| JP (1) | JP4669564B2 (Direct) |
| KR (1) | KR101255879B1 (Direct) |
| CN (2) | CN101541772B (Direct) |
| AU (1) | AU2007323042B2 (Direct) |
| CA (1) | CA2669069C (Direct) |
| DK (2) | DK2094676T3 (Direct) |
| ES (2) | ES2410793T3 (Direct) |
| IL (1) | IL198847A (Direct) |
| MX (1) | MX2009005048A (Direct) |
| TW (1) | TWI460166B (Direct) |
| WO (1) | WO2008062376A2 (Direct) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE43833E1 (en) | 2003-11-21 | 2012-11-27 | Actelion Pharmaceuticals Ltd. | Thiazolidin-4-one derivatives |
| EP1689726B1 (en) | 2003-11-21 | 2010-10-06 | Actelion Pharmaceuticals Ltd. | 5-(benz- (z) -ylidene) -thiazolidin-4-one derivatives as immunosuppressant agents |
| US8912340B2 (en) | 2006-11-23 | 2014-12-16 | Actelion Pharmaceuticals Ltd. | Process for the preparation of 2-imino-thiazolidin-4-one derivatives |
| KR20100134032A (ko) | 2008-03-17 | 2010-12-22 | 액테리온 파마슈티칼 리미티드 | 선별적 ｓ1ｐ₁ 수용체 작동약에 대한 투약 섭생 |
| GB0819182D0 (en) | 2008-10-20 | 2008-11-26 | Actelion Pharmaceuticals Ltd | Crystalline forms |
| PT2885266T (pt) * | 2012-08-17 | 2020-05-29 | Actelion Pharmaceuticals Ltd | Processo para a preparação de (2z,5z)-5-(3-cloro-4-((r)-2,3-di-hidropropoxi)benzilideno)-2-(propilimino)-3-(o-tolil)tiazolidin-4-ona e intermediário utilizado no referido processo |
| MA41139A (fr) | 2014-12-11 | 2017-10-17 | Actelion Pharmaceuticals Ltd | Combinaison pharmaceutique comportant un agoniste sélectif du récepteur sip1 |
| KR20200013086A (ko) | 2014-12-11 | 2020-02-05 | 액테리온 파마슈티칼 리미티드 | 선택적 s1p1 수용체 효능제에 대한 투약 섭생 |
| JOP20190207A1 (ar) | 2017-03-14 | 2019-09-10 | Actelion Pharmaceuticals Ltd | تركيبة صيدلانية تشتمل على بونيسيمود |
| WO2019060147A1 (en) * | 2017-09-19 | 2019-03-28 | Teva Pharmaceuticals Usa, Inc. | NEW CRYSTALLINE POLYMORPHE FROM PONESIMOD |
| US11013723B1 (en) | 2018-10-16 | 2021-05-25 | Celgene Corporation | Solid forms of a thiazolidinone compound, compositions and methods of use thereof |
| US11014897B1 (en) | 2018-10-16 | 2021-05-25 | Celgene Corporation | Solid forms comprising a thiazolidinone compound, compositions and methods of use thereof |
| US11014940B1 (en) | 2018-10-16 | 2021-05-25 | Celgene Corporation | Thiazolidinone and oxazolidinone compounds and formulations |
| US11186556B1 (en) | 2018-10-16 | 2021-11-30 | Celgene Corporation | Salts of a thiazolidinone compound, solid forms, compositions and methods of use thereof |
| CN114040910A (zh) * | 2019-07-10 | 2022-02-11 | 拜耳公司 | 制备2-(苯基亚氨基)-1,3-噻唑烷-4-酮的方法 |
| US20220251053A1 (en) * | 2019-07-10 | 2022-08-11 | Bayer Aktiengesellschaft | Process of preparing 2-(phenylimino)-1,3-thiazolidin-4-ones |
| KR20220093330A (ko) | 2019-10-31 | 2022-07-05 | 이도르시아 파마슈티컬스 리미티드 | Cxcr7 안타고니스트와 s1p1 수용체 조절인자의 조합 |
| KR20200019639A (ko) | 2020-01-30 | 2020-02-24 | 전대연 | 만남의 스마트 도착시스템 |
| MX2022010058A (es) * | 2020-02-18 | 2022-08-25 | Bayer Ag | Procedimiento para la preparacion de 2-(fenilimino)-3-alquil-1,3-t iazolidin-4-onas. |
| US20240368094A1 (en) | 2021-08-17 | 2024-11-07 | Teva Czech Industries S.R.O | Polymorphs of ponesimod |
| EP4212156A1 (en) | 2022-01-13 | 2023-07-19 | Abivax | Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a s1p receptor modulator |
| WO2023152691A1 (en) * | 2022-02-10 | 2023-08-17 | Metrochem Api Pvt Ltd | Process for the preparation of ponesimod and its intermediates thereof |
| CN117924210A (zh) * | 2024-01-22 | 2024-04-26 | 赣南师范大学 | 一种2-亚氨基噻唑烷-4-酮类化合物的制备方法 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3077402A (en) * | 1954-12-06 | 1963-02-12 | Polaroid Corp | Photographic color processes, products, and compositions |
| NL270002A (Direct) | 1960-10-08 | |||
| OA03835A (fr) | 1970-07-17 | 1971-12-24 | Rhone Poulenc Sa | Nouveaux dérivés de la thiazolidine, leur préparation et les compositions qui les contiennent. |
| WO1991017151A1 (en) * | 1990-04-27 | 1991-11-14 | Orion-Yhtymä Oy | New pharmacologically active catechol derivatives |
| TW221689B (Direct) * | 1991-08-27 | 1994-03-11 | Otsuka Pharma Co Ltd | |
| ATE212018T1 (de) * | 1993-02-26 | 2002-02-15 | Otsuka Pharma Co Ltd | Thiazole oder imidazole derivate als maillard reaktion inhibitoren |
| KR960022486A (ko) | 1994-12-29 | 1996-07-18 | 김준웅 | 신규 티아졸리딘-4-온 유도체 |
| US6353006B1 (en) * | 1999-01-14 | 2002-03-05 | Bayer Corporation | Substituted 2-arylimino heterocycles and compositions containing them, for use as progesterone receptor binding agents |
| US6818640B1 (en) | 1999-09-14 | 2004-11-16 | Shionogi & Co., Ltd. | 2-imino-1,3-thiazine derivatives |
| US6380229B1 (en) * | 1999-11-12 | 2002-04-30 | Fujimoto Co., Ltd. | 2-(N-cyanoimino)thiazolidin-4-one derivatives |
| US20050019825A9 (en) * | 2002-03-15 | 2005-01-27 | Qing Dong | Common ligand mimics: pseudothiohydantoins |
| AU2003255528B2 (en) | 2002-07-10 | 2009-07-16 | Merck Serono Sa | Azolidinone-vinyl fused-benzene derivatives |
| GB0217152D0 (en) | 2002-07-24 | 2002-09-04 | Novartis Ag | Organic compounds |
| PL377564A1 (pl) * | 2002-11-22 | 2006-02-06 | Smithkline Beecham Corporation | Nowe związki chemiczne |
| US20040167192A1 (en) * | 2003-01-16 | 2004-08-26 | David Solow-Cordero | Methods of treating conditions associated with an Edg-7 receptor |
| EP1689726B1 (en) * | 2003-11-21 | 2010-10-06 | Actelion Pharmaceuticals Ltd. | 5-(benz- (z) -ylidene) -thiazolidin-4-one derivatives as immunosuppressant agents |
| WO2005082901A1 (en) * | 2004-02-25 | 2005-09-09 | Smithkline Beecham Corporation | Novel chemical compounds |
| WO2006094233A1 (en) * | 2005-03-03 | 2006-09-08 | Sirtris Pharmaceuticals, Inc. | N,n'-dicyclic isothiourea sirtuin modulators |
| KR20100134032A (ko) * | 2008-03-17 | 2010-12-22 | 액테리온 파마슈티칼 리미티드 | 선별적 ｓ1ｐ₁ 수용체 작동약에 대한 투약 섭생 |
| GB0819182D0 (en) * | 2008-10-20 | 2008-11-26 | Actelion Pharmaceuticals Ltd | Crystalline forms |
-
2007
- 2007-11-22 KR KR1020097011745A patent/KR101255879B1/ko active Active
- 2007-11-22 CA CA2669069A patent/CA2669069C/en active Active
- 2007-11-22 US US12/516,055 patent/US8263780B2/en active Active
- 2007-11-22 TW TW096144311A patent/TWI460166B/zh active
- 2007-11-22 ES ES07849225T patent/ES2410793T3/es active Active
- 2007-11-22 EP EP07849225.3A patent/EP2094676B1/en active Active
- 2007-11-22 JP JP2009537744A patent/JP4669564B2/ja active Active
- 2007-11-22 CN CN2007800431941A patent/CN101541772B/zh active Active
- 2007-11-22 WO PCT/IB2007/054752 patent/WO2008062376A2/en not_active Ceased
- 2007-11-22 DK DK07849225.3T patent/DK2094676T3/da active
- 2007-11-22 EP EP12000613.5A patent/EP2489662B1/en active Active
- 2007-11-22 DK DK12000613.5T patent/DK2489662T3/da active
- 2007-11-22 ES ES12000613.5T patent/ES2523401T3/es active Active
- 2007-11-22 AU AU2007323042A patent/AU2007323042B2/en active Active
- 2007-11-22 CN CN2012105461683A patent/CN103087004A/zh active Pending
- 2007-11-22 MX MX2009005048A patent/MX2009005048A/es active IP Right Grant
-
2009
- 2009-05-20 IL IL198847A patent/IL198847A/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| KR101255879B1 (ko) | 2013-04-17 |
| ES2523401T3 (es) | 2014-11-25 |
| WO2008062376A3 (en) | 2008-07-10 |
| BRPI0718986A2 (pt) | 2014-02-11 |
| WO2008062376A2 (en) | 2008-05-29 |
| JP2010510976A (ja) | 2010-04-08 |
| TW200831474A (en) | 2008-08-01 |
| IL198847A (en) | 2015-07-30 |
| ES2410793T3 (es) | 2013-07-03 |
| IL198847A0 (en) | 2010-02-17 |
| US8263780B2 (en) | 2012-09-11 |
| EP2489662A1 (en) | 2012-08-22 |
| TWI460166B (zh) | 2014-11-11 |
| DK2489662T3 (da) | 2014-10-20 |
| CA2669069A1 (en) | 2008-05-29 |
| CN103087004A (zh) | 2013-05-08 |
| EP2489662B1 (en) | 2014-08-06 |
| EP2094676A2 (en) | 2009-09-02 |
| MX2009005048A (es) | 2009-05-25 |
| CN101541772B (zh) | 2013-04-17 |
| CN101541772A (zh) | 2009-09-23 |
| AU2007323042A1 (en) | 2008-05-29 |
| EP2094676B1 (en) | 2013-04-10 |
| AU2007323042B2 (en) | 2012-12-20 |
| KR20090081009A (ko) | 2009-07-27 |
| US20110201821A2 (en) | 2011-08-18 |
| JP4669564B2 (ja) | 2011-04-13 |
| DK2094676T3 (da) | 2013-06-10 |
| US20100317867A1 (en) | 2010-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2669069C (en) | Process for the preparation of 2-imino-thiazolidin-4-one derivatives | |
| US8912340B2 (en) | Process for the preparation of 2-imino-thiazolidin-4-one derivatives | |
| AU2001266345B2 (en) | Five-membered-ring compound | |
| JP2008514610A5 (Direct) | ||
| EP1996567A2 (en) | Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome | |
| EP1991536A2 (en) | Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome | |
| AU2011204370B2 (en) | Hedgehog inhibitors | |
| AU2003232754B2 (en) | Diaminothiazoles | |
| JPH0460990B2 (Direct) | ||
| EP1877364A1 (en) | Phenylacetylene derivatives having mglur5 receptor affinity | |
| US6586456B1 (en) | Aminothiazole derivatives and their use as CRF receptor ligands | |
| WO1998032747A1 (en) | Process for the preparation of thiazole derivatives | |
| CZ2003239A3 (cs) | Způsob přípravy azacykloalkanoylaminothiazolů | |
| EP1694646B1 (en) | Process for the synthesis of pioglitazone hydrogen chloride | |
| JPH1160552A (ja) | チオベンズアミド誘導体の製造方法 | |
| JPH1081673A (ja) | 複素環誘導体、及びそれを含有する制癌剤 | |
| PL209913B1 (pl) | Nowe pochodne 1,1-diokso-4H-1,5,2-benzo[f]ditiazepiny i sposób ich otrzymywania | |
| BRPI0718986B1 (pt) | Processo para a preparação de um composto | |
| MXPA06005590A (en) | 5-(benz- (z) -ylidene) -thiazolidin-4-one derivatives as immunosuppressant agents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |